DCLK3 and central nervous system cancer: Although gepant-class CGRP antagonists have yet to enter neuro-oncology trials, the demonstrable dependence of ADM/CGRP-responsive glioma sub-populations on CLR signalling nominates these agents as credible dual-purpose therapeutics.